newsfilter
← Latest News
GlobeNewswire·

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second